Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Silver Nanoparticles Targets Tumors

By BiotechDaily International staff writers
Posted on 17 Jun 2014
Image: Prostate cancer cells were targeted by two separate silver nanoparticles (red and green), while the cell nucleus was labeled in blue using Hoescht dye (Photo courtesy of UCSB – University of California, Santa Barbara).
Image: Prostate cancer cells were targeted by two separate silver nanoparticles (red and green), while the cell nucleus was labeled in blue using Hoescht dye (Photo courtesy of UCSB – University of California, Santa Barbara).
Scientists have devised a nanoparticle that has a couple of unique, and key, characteristics. Spherical in shape and made up of silver, it is encased in a shell coated with a peptide that enables it to target tumor cells. Moreover, the shell is etchable, therefore, those nanoparticles that do not hit their target can be broken down and eliminated.

The research findings were published June 8, 2014, in the journal Nature Materials. The core of the nanoparticle employs a feature known as plasmonics. In plasmonics, nanostructured metals such as silver and gold resonate in light and concentrate the electromagnetic field near the surface. In this manner, fluorescent dyes are enhanced, appearing about 10 times brighter than their natural state when no metal is present. When the core is etched, the enhancement retreats and the particle becomes dim.

University of California-Santa Barbara’s (UCSB; USA) Ruoslahti Research Laboratory also developed a simple etching technique using biocompatible chemicals to quickly disassemble and take away the silver nanoparticles outside living cells. This method leaves only the intact nanoparticles for imaging or quantification, thus revealing which cells have been targeted and how much each cell internalized.

“The disassembly is an interesting concept for creating drugs that respond to a certain stimulus,” said Gary Braun, a postdoctoral associate in the Ruoslahti Lab in the department of molecular, cellular and developmental biology (MCDB) and at Sanford-Burnham Medical Research Institute. “It also minimizes the off-target toxicity by breaking down the excess nanoparticles so they can then be cleared through the kidneys.”

This method for removing nanoparticles unable to penetrate target cells is unique. “By focusing on the nanoparticles that actually got into cells,” Dr. Braun said, “we can then understand which cells were targeted and study the tissue transport pathways in more detail.”

Various agents are able to pass through the cell membrane by themselves, but many drugs, particularly RNA and DNA genetic drugs, are charged molecules that are stopped by the membrane. These drugs must be taken in through endocytosis, the process by which cells absorb molecules by surrounding them. “This typically requires a nanoparticle carrier to protect the drug and carry it into the cell,” Dr. Braun said. “And that’s what we measured: the internalization of a carrier via endocytosis.”

Because the nanoparticle has a core shell structure, the researchers can vary its exterior coating and compare the efficiency of tumor targeting and internalization. Switching out the surface agent enables the targeting of different diseases—or organisms in the case of bacteria—through the use of different target receptors. According to Dr. Braun, this should become a strategy to optimize drug delivery where the core is a drug-containing vehicle.

“These new nanoparticles have some remarkable properties that have already proven useful as a tool in our work that relates to targeted drug delivery into tumors,” said Erkki Ruoslahti, adjunct distinguished professor in UCSB’s Center for Nanomedicine and MCDB department and at Sanford-Burnham Medical Research Institute. “They also have potential applications in combating infections. Dangerous infections caused by bacteria that are resistant to all antibiotics are getting more common, and new approaches to deal with this problem are desperately needed. Silver is a locally used antibacterial agent and our targeting technology may make it possible to use silver nanoparticles in treating infections anywhere in the body.”

Related Links:

University of California-Santa Barbara



RANDOX LABORATORIES
SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.